Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

NCT04400474 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumor
Anaplastic Thyroid Cancer
Adenocarcinoma
Pheochromocytoma
Paraganglioma

Interventions

DRUG: Cabozantinib 40 mg

Sponsor

Grupo Espanol de Tumores Neuroendocrinos

Collaborators

[object Object]
[object Object]